Multitargeted Anti‐Inflammatory Agents: Novel Pyrazole and Pyrazolo[1,5‐ a ]Pyrimidine Carbonic Anhydrase and COX‐2 Inhibitors With Optimal In Vivo Efficacy and Low Toxicity
Drug Development Research · 2026
DOI: 10.1002/ddr.70214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Mariam M Fakhry und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt. Hauptthemen laut MEDLINE: Carbonic Anhydrase Inhibitors, Pyrazoles, Cyclooxygenase 2 Inhibitors, Pyrimidines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 88 Literaturangaben.
Abstract (Originalsprache)
In this study, three series of pyrazole and pyrazolo[1,5‐ a ]pyrimidine derivatives 6a‐f , 8a‐f , and 10a‐f were designed and synthesized in response to the global need to safe and potent anti‐inflammatory agents. A rational design strategy was employed to synthesize compounds that inhibit inflammation‐related carbonic anhydrase isoforms (II, IX, and XII) alongside achieving selective inhibition of cyclooxygenase‐2 (COX‐2). Remarkably, the sulfonamide derivatives 6f, 8d, and 10e displayed high activity as carbonic anhydrase inhibitors against isoforms II, IX and XII in addition to their potent and selective COX‐2 inhibition effect (IC 50 = 57–87 nM; SI = 175–100). Among them, the multitargeted inhibitor 10e (COX‐2, IC 50 = 57 nM; CA II, K i = 49.9 nM; CA IX, K i = 67.5 nM; CA XII, K i = 54.6 nM) was further evaluated in vivo and demonstrated strong dual anti‐inflammatory and analgesic properties, with a rapid onset of action within the first hour and sustained efficacy over 5 h. Toxicological studies revealed that compound 10e possessed a favorable safety profile, showing no significant adverse effects on liver, kidney, or cardiac functions and minimal ulcerogenic potential. Molecular docking studies further supported these findings by confirming key binding interactions with CA II, IX, XII, and COX‐2 active sites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt.
- Laboratoire de Génie Chimique, Université de Toulouse, Toulouse INP, CNRS, LGC, Toulouse, France.
- Department of pharmaceutical chemistry, College of Pharmacy, University of Kut, Waist, Iraq.
- Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Firenze, Italy.
- Department of Applied Organic Chemistry Department, National Research Center, Dokki, Cairo, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, Egypt.
ORCID-Profile: Mariam M Fakhry, Claudiu T Supuran
Zitieren
APA
Fakhry, M. M., Said, M. A., Ammara, A., Bouajila, J., Supuran, C. T., Abdel-Aziz, H. A., & Abou-Seri, S. M. (2026). Multitargeted Anti‐Inflammatory Agents: Novel Pyrazole and Pyrazolo[1,5‐ a ]Pyrimidine Carbonic Anhydrase and COX‐2 Inhibitors With Optimal In Vivo Efficacy and Low Toxicity. Drug Development Research. https://doi.org/10.1002/ddr.70214
Vancouver
Fakhry MM, Said MA, Ammara A, Bouajila J, Supuran CT, Abdel-Aziz HA, et al. Multitargeted Anti‐Inflammatory Agents: Novel Pyrazole and Pyrazolo[1,5‐ a ]Pyrimidine Carbonic Anhydrase and COX‐2 Inhibitors With Optimal In Vivo Efficacy and Low Toxicity. Drug Development Research. 2026. doi:10.1002/ddr.70214
BibTeX
@article{Fakhry2026,
author = {Fakhry, Mariam M and Said, Mohamed A and Ammara, Andrea and Bouajila, Jalloul and Supuran, Claudiu T and Abdel-Aziz, Hatem A and Abou-Seri, Sahar M},
title = {Multitargeted Anti‐Inflammatory Agents: Novel Pyrazole and Pyrazolo[1,5‐ a ]Pyrimidine Carbonic Anhydrase and COX‐2 Inhibitors With Optimal In Vivo Efficacy and Low Toxicity},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70214}
}
EUVIMED